• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6496.TWO
Share

Excelsior Biopharma Inc. Stocks

NT$ 24.2Last Updated 21.10.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 34.25M

NT$ 24.2
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Excelsior Biopharma Inc., established in 1988 and headquartered in Taipei, Taiwan, functions as a pharmaceutical enterprise with a global market presence, encompassing Taiwan, China, and other international regions. The company offers a comprehensive range of healthcare solutions, including prescription and over-the-counter medications, medical devices, nutritional supplements, and various medical supplies. Excelsior addresses numerous therapeutic areas such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, otorhinolaryngology, and infectious disease management. Its product line also features specialized diagnostic kits under the Actim brand for identifying conditions like influenza virus, fecal occult blood, acute pancreatitis, and for assessing preterm or full-week delivery and early membrane rupture. Moreover, the company provides oral hygiene products, including toothpaste, mouthwash, and gels, under the Oral7 name. Beyond product sales, Excelsior is involved in the import and export of active pharmaceutical ingredients, as well as engaging in technological research, facilitating pharmaceutical technology transfer, and participating in collaborative development and improvement initiatives. The company adopted its current name, Excelsior Biopharma Inc., in June 2003, having previously been known as Excelsior Enterprise Co., Ltd.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.10.2026 22:53

"Ambitions Greater Than Anyone Else's": JPMorgan Expects SpaceX Shares to Triple in Value

21.10.2026 22:20

Berkshire Hathaway shares hit a new record high—for the first time since Buffett announced his retirement

21.10.2026 22:08

A Left or Right Turn: What Investors Are Watching Ahead of the French Presidential Election

21.10.2026 21:10

Shares of Ray-Ban had their best day since 2008. Should you buy them?

21.10.2026 20:20

The Old World on New Chips: How Nvidia Is Driving the Industrial Revolution in Europe

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026